BioSpace News Archive

The Swiss contract manufacturer’s cash deal for Roche’s facility in Vacaville, California, is one of the world’s largest manufacturing sites for biologics—a major growth driver for Lonza and other CDMOs.

Neuroscientists have established in recent decades the idea that some of each day’s experiences are converted by the brain into permanent memories during sleep the same night.

Galapagos NV publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm and 3:00 pm, respectively, at the registered office of the Company.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.

Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023.

INmune Bio Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its financial results for the year ended December 31, 2023 and provides a business update.

Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC) today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET.

CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, announced that Company’s Management will participate in the following three investor conferences during the month of April.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and highlighted recent corporate updates and upcoming milestones.